$0.35
BioAtla
Performance
Dividends
1W
1M
YTD
1Y
3Y
9/36
Growth
Score
8/36
Dividend
Score
Valuation
PE Ratio
-0.33
PS Ratio
1.88
RSI
-
0
PEG Ratio
-0.02
0
PRG Ratio
-0.01
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
0
Rule
of 40
23.97%
3
Gross Margin
97.92%
2
Current Ratio
2.35
Return on Assets
-161.6%
Return on Equity
-357.92%
Return on inv. Capital
-293.81%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 11.00M
2019
2020
2021
2022
2023
2024
5
Net Income 2024 -69.78M
2019
2020
2021
2022
2023
2024
5
Gross Profit 2024 10.07M
2019
2020
2021
2022
2023
2024
5
Events
BCAB
BioAtla
in 264 days
after market close
Earnings per Share is expected with - and revenue with - .
BCAB
BioAtla
in 224 days
after market close
Earnings per Share is expected with - and revenue with - .
BCAB
BioAtla
in 85 days
after market close
Earnings per Share is expected with -$0.29 -31.82% and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
16.12.2020
MaketCap
20.71M
Country
US
CEO
Jay M. Short
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Updated 10.08.2025